CURE Pharmaceutical subsidiary, Oak Therapeutics, completes critical milestone in Phase 1 of NIH grant to develop oral dissolvable strip for TB

OXNARD, Calif., Aug. 22, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company, today announced that its subsidiary company, Oak Therapeutics, has completed a critical milestone of its Phase I Small Business Innovative Research Contract (SBIR) from the National Institutes of Health/National Institute of Allergy and Infectious Diseases  (NIH/ NIAID) to develop a formulation for 300 mg of Isoniazid in a rapidly dissolving Oral Dissolvable Strip (ODS) as an anti-tuberculosis treatment option.